You are here

Article Text

Article menu

Download PDFPDF

Oral Presentation
WT1 peptide analogue WT1-126Y enhances leukemia lysis
  1. Ghofran Alqudaihi1,
  2. Cynthia Lehe2,
  3. Monther Al-Alwan1,
  4. Hazem Ghebeh1,
  5. Anne Dickinson3 and
  6. Said Dermime4
  1. Aff1 grid.415310.20000000121914301King Faisal Specialist Hospital & Research center Riyadh Saudi Arabia
  2. Aff2 grid.452356.30000000405181285Dasman Diabetes Institute Kuwait
  3. Aff3 grid.1006.70000000104627212University of Newcastle upon Tyne Newcastle Upon Tyne UK
  4. Aff4 grid.415280.a0000000404023867King Fahad Specialist Hospital Dammam Saudi Arabia

https://doi.org/10.1186/2051-1426-2-S1-O3

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Meeting abstracts

    Background

    The Wilms Tumour Antigen 1 (WT1) has been shown to be expressed at low levels in some normal cells. Therefore, many of the potential CTL epitopes against this antigen may be absent or suboptimal. To this end, different groups introduced modifications in the sequence of the anchor positions of these “sub-optimal” peptides to improve their binding to HLA class I molecules and to increase their immunogenicity.

    Aim

    To explore the feasibility of using an approach that enhances the immunogenicity of low-avidity restricted peptides without altering their antigenic specificity. This approach consists of replacing the first amino acid of two known HLA-A0201-restricted WT1-derived peptides (Db126 and WH187) by a tyrosine (Y).

    Findings

    The modified WT1-Db126 showed enhanced binding ability to the HLA-A*0201 molecule, increased the frequency of IFN-γ producing cytotoxic T lymphocyte (CTL) and boosted the lytic activity of the generated CTL against HLA-matched leukaemia cells. Interestingly, the CTL line generated with the modified epitope was able to recognize the wild-type peptide presented by target cells.

    Conclusions

    This study provide evidence that peptide modification results in a better immune response against cancer and further support the use of this strategy as a potential approach for the development of a leukemia-vaccine.